Aardvark Therapeutics Files S-1 for Potential Offering

Ticker: AARD · Form: S-1 · Filed: Jan 23, 2025 · CIK: 1774857

Aardvark Therapeutics, INC. S-1 Filing Summary
FieldDetail
CompanyAardvark Therapeutics, INC. (AARD)
Form TypeS-1
Filed DateJan 23, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$13.6 million, $7.2 m, $5.2 million, $11.8 m, $37.7 million
Sentimentneutral

Sentiment: neutral

Topics: ipo-filing, pharmaceuticals, registration-statement

TL;DR

Aardvark Therapeutics just filed an S-1, looks like they're gearing up for an IPO/offering.

AI Summary

Aardvark Therapeutics, Inc., incorporated in Delaware, filed an S-1 registration statement on January 23, 2025. The company, located at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122, is in the pharmaceutical preparations industry. The filing indicates a potential public offering, though specific dollar amounts and dates for the offering are not detailed in this excerpt.

Why It Matters

This S-1 filing signals Aardvark Therapeutics' intention to raise capital through a public offering, which could fund its drug development pipeline and future operations.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, Aardvark Therapeutics is likely in the early stages of development, carrying inherent risks associated with drug discovery and regulatory approval.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this S-1 filing for Aardvark Therapeutics, Inc.?

The S-1 filing is a registration statement filed with the SEC, indicating Aardvark Therapeutics, Inc.'s intention to offer its securities to the public, likely for capital raising purposes.

When was this S-1 filing submitted to the SEC?

The S-1 filing was submitted to the SEC on January 23, 2025.

Where is Aardvark Therapeutics, Inc. headquartered?

Aardvark Therapeutics, Inc. is headquartered at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122.

Who is the Chief Executive Officer of Aardvark Therapeutics, Inc.?

The Chief Executive Officer of Aardvark Therapeutics, Inc. is Tien-Li Lee, M.D.

What industry does Aardvark Therapeutics, Inc. operate in, according to its SIC code?

Aardvark Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.

Filing Stats: 4,494 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2025-01-23 16:57:41

Key Financial Figures

Filing Documents

Underwriting

Underwriting Discounts and Commissions (1) Proceeds to Aardvark Per Share $ $ $ Total $ $ $ (1) See the section titled Underwriters for a description of the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to an additionalshares of our common stock solely to cover over-allotments, if any. Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares of common stock to purchasers on , 2025. MORGAN STANLEY BOFA SECURITIES CANTOR RBC CAPITAL MARKETS , 2025 Table of Contents TABLE OF CONTENTS PROSPECTUS PAGE PROSPECTUS SUMMARY 1

RISK FACTORS

RISK FACTORS 12 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 87 MARKET AND INDUSTRY DATA 90

USE OF PROCEEDS

USE OF PROCEEDS 91 DIVIDEND POLICY 93 CAPITALIZATION 94

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 99

BUSINESS

BUSINESS 116 MANAGEMENT 163

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 175 PAGE CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 195 PRINCIPAL STOCKHOLDERS 199

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 202 SHARES ELIGIBLE FOR FUTURE SALE 209 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 212 UNDERWRITERS 217 LEGAL MATTERS 228 EXPERTS 228 WHERE YOU CAN FIND ADDITIONAL INFORMATION 228 INDEX TO FINANCIAL STATEMENTS F-1 Through and including , 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. You should rely only on the information contained in this prospectus and any free writing prospectus that we may provide to you in connection with this offering. We have not, and the underwriters have not, authorized anyone to provide you with different information or to make any other representations, and we and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in th

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing